Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy.
Szarvas T, Csizmarik A, Váradi M, Fazekas T, Hüttl A, Nyirády P, Hadaschik B, Grünwald V, Tschirdewahn S, Shariat SF, Sevcenco S, Maj-Hes A, Kramer G. Szarvas T, et al. Among authors: sevcenco s. Urol Oncol. 2021 May;39(5):296.e11-296.e19. doi: 10.1016/j.urolonc.2020.09.005. Epub 2020 Oct 9. Urol Oncol. 2021. PMID: 33046366 Free article.
Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer.
Szarvas T, Sevcenco S, Módos O, Keresztes D, Nyirády P, Csizmarik A, Ristl R, Puhr M, Hoffmann MJ, Niedworok C, Hadaschik B, Maj-Hes A, Shariat SF, Kramer G. Szarvas T, et al. Among authors: sevcenco s. BJU Int. 2018 Oct;122(4):695-704. doi: 10.1111/bju.14415. Epub 2018 Jun 20. BJU Int. 2018. PMID: 29802777
Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration-resistant prostate cancer.
Keresztes D, Csizmarik A, Nagy N, Módos O, Fazekas T, Bracht T, Sitek B, Witzke K, Puhr M, Sevcenco S, Kramer G, Shariat S, Küronya Z, Takács L, Tornyi I, Lázár J, Hadaschik B, Lászik A, Szűcs M, Nyirády P, Szarvas T. Keresztes D, et al. Among authors: sevcenco s. J Cell Mol Med. 2022 Feb;26(4):1332-1337. doi: 10.1111/jcmm.17141. Epub 2021 Dec 30. J Cell Mol Med. 2022. PMID: 34970839 Free PMC article.
Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancer.
Csizmarik A, Keresztes D, Nagy N, Bracht T, Sitek B, Witzke K, Puhr M, Tornyi I, Lázár J, Takács L, Kramer G, Sevcenco S, Maj-Hes A, Jurányi Z, Hadaschik B, Nyirády P, Szarvas T. Csizmarik A, et al. Among authors: sevcenco s. Int J Cancer. 2022 Oct 15;151(8):1405-1419. doi: 10.1002/ijc.34159. Epub 2022 Jun 21. Int J Cancer. 2022. PMID: 35689436 Free PMC article.
40 results